Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K.

Invest New Drugs. 2012 Jun;30(3):1138-43. doi: 10.1007/s10637-010-9619-8. Epub 2010 Dec 21.

PMID:
21170759
2.

[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].

Yang QY, Shen D, Sai K, Mu YG, Jiang XB, Zhang XH, Chen ZP.

Zhonghua Zhong Liu Za Zhi. 2011 Mar;33(3):232-5. Chinese.

PMID:
21575527
3.

Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer.

Su D, Jiao SC, Wang LJ, Shi WW, Long YY, Li J, Bai L.

Tumour Biol. 2014 Mar;35(3):2313-8. doi: 10.1007/s13277-013-1306-x. Epub 2013 Oct 19.

PMID:
24142531
4.

A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.

You B, Brade A, Magalhaes JM, Siu LL, Oza A, Lovell S, Wang L, Hedley DW, Nicacio LV, Chen EX.

Invest New Drugs. 2011 Oct;29(5):996-1003. doi: 10.1007/s10637-010-9444-0. Epub 2010 May 8.

PMID:
20454832
5.

Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K.

Int J Clin Pharmacol Ther. 2010 Jul;48(7):473-5. No abstract available.

PMID:
20557849
6.

A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.

Muro K, Yoshino T, Doi T, Shirao K, Takiuchi H, Hamamoto Y, Watanabe H, Yang BB, Asahi D.

Jpn J Clin Oncol. 2009 May;39(5):321-6. doi: 10.1093/jjco/hyp016. Epub 2009 Mar 14.

7.

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.

Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ.

Cancer. 2007 Sep 1;110(5):980-8.

8.

Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer.

Hecht JR, Mitchell E, Neubauer MA, Burris HA 3rd, Swanson P, Lopez T, Buchanan G, Reiner M, Gansert J, Berlin J.

Clin Cancer Res. 2010 Apr 1;16(7):2205-13. doi: 10.1158/1078-0432.CCR-09-2017. Epub 2010 Mar 23. Erratum in: Clin Cancer Res.2010 May 15;16(10):2917.

9.

Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.

Bartels U, Wolff J, Gore L, Dunkel I, Gilheeney S, Allen J, Goldman S, Yalon M, Packer RJ, Korones DN, Smith A, Cohen K, Kuttesch J, Strother D, Baruchel S, Gammon J, Kowalski M, Bouffet E.

Neuro Oncol. 2014 Nov;16(11):1554-9. doi: 10.1093/neuonc/nou091. Epub 2014 May 20.

10.

Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.

Wagener DJ, Hoogenraad WJ, Rougier P, Lusinchi A, Taal BG, Veenhof CH, de Graeff A, Conroy T, Curran D, Sahmoud T, Wils J.

Eur J Cancer. 1996 Jul;32A(8):1310-3.

PMID:
8869091
11.

Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.

Wang HP, Zhang L, Wang YX, Tan FL, Xia Y, Ren GJ, Hu P, Jiang J, Wang MZ, Xiao Y.

Chin Med J (Engl). 2011 Jul 5;124(13):1933.

12.

A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors.

Okamoto W, Yoshino T, Takahashi T, Okamoto I, Ueda S, Tsuya A, Boku N, Nishio K, Fukuoka M, Yamamoto N, Nakagawa K.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1063-71. doi: 10.1007/s00280-013-2277-8. Epub 2013 Sep 18.

PMID:
24046058
13.

A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.

Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C.

Br J Cancer. 2000 Aug;83(4):458-62.

14.

A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer.

Shinchi H, Maemura K, Mataki Y, Kurahara H, Sakoda M, Ueno S, Hiraki Y, Nakajo M, Natsugoe S, Takao S.

J Hepatobiliary Pancreat Sci. 2012 Mar;19(2):152-8. doi: 10.1007/s00534-011-0400-y.

PMID:
21647560
15.

Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.

Peschel C, Hartmann JT, Schmittel A, Bokemeyer C, Schneller F, Keilholz U, Buchheidt D, Millan S, Izquierdo MA, Hofheinz RD.

Lung Cancer. 2008 Jun;60(3):374-80. Epub 2007 Dec 3.

PMID:
18054408
16.

A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma.

Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, Senft C, Geletneky K, Braun C, Hartung JG, Reuter D, Metz MW, Bach F, Pietsch T.

Eur J Cancer. 2015 Mar;51(4):522-32. doi: 10.1016/j.ejca.2014.12.019. Epub 2015 Jan 20.

PMID:
25616647
17.

Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C.

J Clin Oncol. 2007 Jan 20;25(3):326-31.

18.

A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer.

Lutz MP, Königer M, Muche R, Ellenrieder V, Steinkamp M, Adler G, Gress TM.

Z Gastroenterol. 1999 Oct;37(10):993-7.

PMID:
10549093
19.

Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.

Solomón MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, Salva S, Domíngez R, Alert J, Marinello JJ, Catalá M, Griego MG, Martell JA, Luaces PL, Ballesteros J, de-Castro N, Bach F, Crombet T.

BMC Cancer. 2013 Jun 19;13:299. doi: 10.1186/1471-2407-13-299.

20.

Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.

Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, Bergé Y, Roda D, Russell-Yarde F, Hollingsworth S, Baselga J, Umana P, Manenti L, Tabernero J.

J Clin Oncol. 2011 Oct 1;29(28):3783-90. doi: 10.1200/JCO.2011.34.8888. Epub 2011 Sep 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk